Altered cellular VEGF dynamics in Chronic Obstructive Pulmonary Disease
Maria del Pilar Romano, Pia Ecke, Ellen TufvessoniD, Sukhwinder Singh SohaliD, Leif Hilding BjermeriD, M. V. SchmidtiD, Gunilla Westergren‐ThorssoniD, Anna‐Karin Larsson‐CallerfeltiD
Abstract
Pulmonary vascular remodelling is common in patients with chronic obstructive pulmonary disease (COPD). Vascular endothelial growth factors (VEGFs) are key mediators in angiogenesis and vascular remodelling and exist in different isoforms. VEGF-A is the most potent angiogenic member binding to VEGF receptor 2 (VEGFR2). There are, however, few studies on other isoforms, as VEGF-C, and its receptor VEGFR3 in COPD and subsequent impact of cAMP therapies on VEGF isoforms. Our aim was to evaluate the VEGF isoform synthesis in primary distal lung fibroblasts from control subjects (non-smokers (n=6) and ex-smokers (n=4), and COPD subjects with GOLD stage II (n=4) or GOLD stage IV (n=6), and the expression of VEGFR2 and VEGFR3 in human lung tissue. Primary lung fibroblasts were exposed to the cAMP generating therapies formoterol, iloprost, or roflumilast, the adenylyl cyclase activator forskolin or to transforming growth factor (TGF)-b1. VEGF isoforms were evaluated with ELISA. VEGF-C release was not significantly altered by TGF-{beta}1, in contrast to the increased levels of VEGF-A, in all fibroblasts. VEGF-C was significantly decreased by iloprost, forskolin and formoterol, whereas VEGF-A was significantly increased by iloprost and forskolin, with differences in release pattern between and within fibroblasts from control and COPD subjects. Exposure to VEGF-C specifically towards VEGFR3 decreased proliferative rate in human lung fibroblasts and bronchial epithelial cells. VEGFR2 and VEGFR3 were both present in parenchymal lung tissue and VEGFR2 in pulmonary blood vessels. in both healthy and COPD, whereas there was elevated expression of VEGFR3 in bronchial epithelium. In conclusion, TGF-{beta}1 and cAMP generating compounds have significant effects on VEGF-C and VEGF-A synthesis, which appear dysregulated in lung fibroblasts from ex-smokers and patients with COPD. Increased VEGFR3 expression in the bronchial epithelium in lung tissue, and studies into their functional impact, warrants further investigations.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Direct Effects of Cigarette Smoke in Pulmonary Arterial Cells alter Vascular Tone through Arterial Remodeling and Kv7.4 Channel Dysregulation.
J. Sevilla-Montero, D. Labrousse-Arias, … M. J. Calzada·bioRxiv·Feb 21, 2019
- Fibrocyte accumulation in bronchi: a cellular hallmark of COPD
Isabelle Dupin, Matthieu Thumerel, … Patrick Berger·bioRxiv·Oct 23, 2018
- Connective-Tissue Growth Factor (CTGF/CCN2) Contributes to TGF-β1-Induced Lung Fibrosis
T. Yanagihara, S. G. Chong, … M. R. Kolb·bioRxiv·Jul 4, 2020
- Imbalance between IL-36 receptor agonist and antagonist drives neutrophilic inflammation in COPD
J. R. Baker, P. S. Fenwick, … L. E. Donnelly·bioRxiv·Oct 6, 2021
- Lipogenic Lung Fibroblast-derived Extracellular Vesicles Mitigate Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Pathologies through LAT1-mediated Alveolar Type II Cell Restoration
Shota Fujimoto, Yuta Hirano, … Yu Fujita·bioRxiv·Jun 17, 2024
- CXCR4 blockade alleviates pulmonary and cardiac outcomes in early COPD